​

Neuphoria Therapeutics Ownership | Who Owns Neuphoria Therapeutics?

OverviewFinancialsChart

Neuphoria Therapeutics Ownership Summary

Neuphoria Therapeutics is owned by 23.61% institutional investors, 7.70% insiders, and 68.69% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 19.30% of NEUP shares.

NEUP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNeuphoria Therapeutics23.61%7.70%68.69%
SectorHealthcare Stocks 35.49%11.75%52.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Lynx1 capital management lp875.33K19.30%$3.56M
Armistice capital1.23M12.93%$940.92K
Advisorshares investments155.37K3.42%$632.34K
Point72 asset management316.00K3.33%$242.37K
Shay capital151.01K3.33%$614.61K
Balyasny asset management142.18K3.13%$578.68K
Geode capital management52.01K1.15%$211.67K
Ikarian capital47.44K1.05%$193.09K
Vanguard fiduciary trust33.59K0.74%$136.71K
Fny investment advisers26.50K0.58%$107.00K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Lynx1 capital management lp875.33K0.56%$3.56M
Advisorshares investments155.37K0.12%$632.34K
Shay capital151.01K0.05%$614.61K
Fny investment advisers26.50K0.05%$107.00K
Ikarian capital47.44K0.02%$193.09K
Armistice capital1.23M0.01%$940.92K
Merck10.03K0.01%$40.81K
Virtu financial12.03K0.00%$49.00K
Balyasny asset management142.18K0.00%$578.68K
Boothbay fund management14.00K0.00%$56.98K

Top Buyers

HolderShares% AssetsChange
Armistice capital1.23M0.01%1.23M
Balyasny asset management142.18K0.00%142.18K
Geode capital management52.01K-34.70K
Vanguard fiduciary trust33.59K-33.59K
Advisorshares investments155.37K0.12%21.17K

Top Sellers

HolderShares% AssetsChange
Diadema partners lp---50.00K
Two sigma securities---26.04K
Lewis asset management---23.00K
Shay capital151.01K0.05%-18.05K
Jane street group---16.60K

New Positions

HolderShares% AssetsChangeValue
Armistice capital1.23M0.01%1.23M$940.92K
Balyasny asset management142.18K0.00%142.18K$578.68K
Vanguard fiduciary trust33.59K-33.59K$136.71K
Citadel advisors19.33K-19.33K$78.68K
Virtu financial12.03K0.00%12.03K$49.00K

Sold Out

HolderChange
Tower research capital llc (trc)-1.40K
Beacon pointe advisors-10.00K
Xtx topco-12.01K
Persistent asset partners-13.40K
Bridgeway capital management-14.75K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20266-71.43%1,070,935-26.95%232.26%4-77.78%--100.00%
Dec 31, 20252140.00%1,465,999650.49%3242.73%1863.64%1-
Sep 30, 20251566.67%195,3389.76%87.23%11266.67%1-50.00%
Jun 30, 2025928.57%177,9639.10%1010.86%3-2100.00%
Mar 31, 20257-163,114104.61%1041.65%3-57.14%1-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 21, 2025Lynx1 Capital Management LP-Buy$3.28M

Insider Transactions Trends

DateBuySell
2026 Q1--
2025 Q41-
2025 Q3--
2025 Q2--

NEUP Ownership FAQ

Who owns the most shares of Neuphoria Therapeutics?

Neuphoria Therapeutics’s largest shareholders are Lynx1 capital management lp (875.33K shares, 19.30%), Armistice capital (1.23M shares, 12.93%), and Advisorshares investments (155.37K shares, 3.42%). Together, they hold 35.65% of Neuphoria Therapeutics’s total shares outstanding.

Does Blackrock own Neuphoria Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Neuphoria Therapeutics.

Who is Neuphoria Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is Neuphoria Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.56% of its assets in 875.33K Neuphoria Therapeutics shares, valued at 3.56M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools